Days after halting Biogen’s BACE inhibitor program for Alzheimer’s disease, the Cambridge-based company stopped a clinical trial in idiopathic pulmonary fibrosis due to safety reasons.

The U.S. Food and Drug Administration gave the thumbs-up to Boehringer Ingelheim’s Ofev (nintedanib) for systemic sclerosis-associated interstitial lung disease.

The launch of Dupixent, pediatric vaccine sales and continued growth in Sanofi’s multiple sclerosis franchise were the strongest revenue drivers in third-quarter 2017.

Global Blood Therapeutics announced the shuttering of its GBT440 program to treat idiopathic pulmonary fibrosis (IPF). However, the company will continue investigating the drug in sickle cell disease.

Shares of Galapagos NV were up more than 10 percent after the company announced positive results from its Phase IIa idiopathic pulmonary fibrosis trial.

Roche is offloading some rights to what was once one of its top drug prospects, lebrikizumab, for payments that could total more than $1 billion after the medicine produced only lackluster results in an asthma study during 2016.

Roche said a new Esbriet tablet formulation was approved in Europe for mild to moderate idiopathic pulmonary fibrosis (IPF), a fatal condition that causes irreversible, progressive scarring of the lungs.

Privately held DS Biopharma is spinning out a new company called Afimmune that is focused solely on fibrotic conditions such as NASH and pulmonary disorders including COPD and IPF.